Want to see AVTR full AI Analyst Report?
Top Page
Avantor
(NYSE:AVTR)
Select Model
Select Model
Rating:64Neutral
Price Target:
$16.50
▲(12.94% Upside)
Action:Reiterated
Date:09/21/26
AVTR scores in the mid-range primarily because financial performance is strained by recent losses and pressured margins, even though cash flow remains positive and leverage has improved. Technicals are a clear positive with strong trend strength across moving averages and supportive momentum. The latest earnings call adds support via raised guidance and reaffirmed free-cash-flow targets, while valuation remains a weak point due to negative earnings and no stated dividend yield.
Positive Factors
Mission-Critical Recurring Demand
Avantor’s consumables, bioprocessing materials, and procurement services are integrated into recurring research and manufacturing activity. Qualification requirements, switching costs, and long-term customer relationships can support repeat purchasing and provide durable revenue visibility across regulated end markets.
Negative Factors
Sustained Profitability Deterioration
The shift from solid profitability in 2022–2024 to large losses in 2025 and TTM 2026 weakens earnings quality and reduces financial resilience. Gross margins also remain below earlier levels, suggesting that expense, mix, and operating pressures may persist even as revenue stabilizes.
Read all positive and negative factors
Positive Factors
Negative Factors
Mission-Critical Recurring Demand
Avantor’s consumables, bioprocessing materials, and procurement services are integrated into recurring research and manufacturing activity. Qualification requirements, switching costs, and long-term customer relationships can support repeat purchasing and provide durable revenue visibility across regulated end markets.
Read all positive factors
Avantor Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how much each business segment contributes to total revenue, indicating the company’s diversification and which segments are leading growth or facing headwinds.
Shows how much each business segment contributes to total revenue, indicating the company’s diversification and which segments are leading growth or facing headwinds.
Data provided by:
The Fly
The FlyAvantor (AVTR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.17B
Dividend YieldN/A
Average Volume (3M)7.79M
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue Growth-1.57%
EPS Growth-183.83%
CountryUS
Employees13,500
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.84
Shares Outstanding676,358,800
10 Day Avg. Volume9,356,179
30 Day Avg. Volume7,787,279
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.40
Price to Sales (P/S)1.19
P/FCF Ratio15.70
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$13.79Price Target Upside-5.60% Downside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)0.81
Revenue Forecast (FY)$6.59B
Avantor Business Overview & Revenue Model
Company Description
Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide arr...
How the Company Makes Money
Avantor primarily makes money by selling products and services used in laboratory research, testing, and biopharmaceutical manufacturing. Its revenue is largely generated from (1) consumables and repeat-purchase items (e.g., chemicals, reagents, l...
Avantor Earnings Call Summary
Earnings Call Date:Jul 29, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 28, 2026
Earnings Call Sentiment Positive
The call conveyed tangible operational progress and improving commercial momentum, highlighted by VWR's return to organic growth, strong free cash flow generation, measurable Revival-driven productivity gains, and raised full-year guidance. These positives are balanced against near-term headwinds in the BMP segment from discrete order normalization, ongoing inflationary and FX pressures, and leverage that remains above the company's target. Management expressed confidence in accelerating growth into the second half and into 2027, supported by order momentum and execution improvements.Positive Updates
Revenue and Top-Line Performance
Q2 revenue of $1.69 billion; reported revenue up 0.5% year-over-year while organic revenue declined 0.4%. VWR Distribution & Services grew 1.7% organically in Q2 and drove better-than-expected top-line results.
Negative Updates
Organic Revenue Pressure Consolidated
Consolidated organic revenue declined 0.4% in Q2, reflecting mixed end-market dynamics and discrete order normalization in some BMP businesses.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue and Top-Line Performance
Q2 revenue of $1.69 billion; reported revenue up 0.5% year-over-year while organic revenue declined 0.4%. VWR Distribution & Services grew 1.7% organically in Q2 and drove better-than-expected top-line results.
Read all positive updates
Company Guidance
Avantor raised its 2026 outlook, now expecting organic revenue growth of -0.5% to +0.5%, adjusted EPS of $0.80–$0.83 and free cash flow of $500–$550 million (Q2 FCF was $143M, $152M excl. restructuring), while keeping adjusted EBITDA margin guidance unchanged; Q3 EPS is guided to $0.20–$0.21 assuming ~250 basis points of company organic growth in Q3, FX headwinds of about 125 bps to Q3 reported revenue and ~50 bps to full‑year reported revenue, a weighted average diluted share count of ~677 million, and modestly lower net interest expense vs. 2025. Management reiterated that VWR should accelerate sequentially (VWR was +1.7% organic in Q2) and BMP should return to growth in H2 (BMP was -5.6% organic in Q2), noted BMP facing discrete headwinds of ~150 bps in Q3 and ~400 bps in Q4 in electronic materials, and emphasized capital allocation priorities: continue investing for growth, target adjusted net leverage below 3x (ended Q2 at 3.3x with $3.4B net debt after $112M debt repayment in Q2 and nearly $500M repaid over the trailing 12 months).Avantor Financial Statement Overview
Summary
Income Statement
36
Negative
Balance Sheet
58
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.56B | 6.55B | 6.78B | 6.97B | 7.51B | 7.39B |
| Gross Profit | 2.09B | 2.14B | 2.28B | 2.36B | 2.60B | 2.50B |
| EBITDA | 125.30M | 138.70M | 1.48B | 1.10B | 1.52B | 1.35B |
| Net Income | -578.00M | -530.20M | 711.50M | 321.10M | 686.50M | 572.60M |
Balance Sheet | ||||||
| Total Assets | 11.60B | 11.79B | 12.11B | 12.97B | 13.46B | 13.90B |
| Cash, Cash Equivalents and Short-Term Investments | 306.80M | 365.40M | 261.90M | 262.90M | 372.90M | 301.70M |
| Total Debt | 3.70B | 3.95B | 4.06B | 5.54B | 6.29B | 7.02B |
| Total Liabilities | 5.97B | 6.23B | 6.16B | 7.72B | 8.61B | 9.70B |
| Stockholders Equity | 5.63B | 5.57B | 5.96B | 5.25B | 4.86B | 4.20B |
Cash Flow | ||||||
| Free Cash Flow | 454.70M | 495.00M | 692.00M | 723.60M | 710.20M | 842.50M |
| Operating Cash Flow | 597.00M | 623.80M | 840.80M | 870.00M | 843.60M | 953.60M |
| Investing Cash Flow | -143.00M | -130.50M | 438.90M | -143.70M | -109.60M | -4.12B |
| Financing Cash Flow | -588.50M | -409.40M | -1.28B | -843.70M | -648.70M | 3.22B |
Avantor Technical Analysis
Positive
14.61
Price Trends
14.29
Positive
11.89
Positive
10.72
Positive
Market Momentum
0.27
Positive
53.47
Neutral
39.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVTR, the sentiment is Positive. The current price of 14.61 is below the 20-day moving average (MA) of 15.18, above the 50-day MA of 14.29, and above the 200-day MA of 10.72, indicating a neutral trend. The MACD of 0.27 indicates Positive momentum. The RSI at 53.47 is Neutral, neither overbought nor oversold. The STOCH value of 39.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVTR.
Avantor Risk Analysis
Avantor disclosed 39 risk factors in its most recent earnings report. Avantor reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Avantor Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $25.69B | 46.38 | 18.51% | 0.24% | 12.42% | 17.07% | |
70 Outperform | $1.80B | 36.07 | 13.29% | ― | 0.17% | ― | |
68 Neutral | $5.45B | 37.38 | 8.94% | 0.31% | 14.73% | 7.43% | |
66 Neutral | $10.00B | 245.54 | 1.98% | ― | 16.49% | ― | |
64 Neutral | $10.17B | -18.29 | -10.34% | ― | -1.57% | -183.83% | |
58 Neutral | $1.51B | -14.09 | -7.56% | 0.37% | 1.47% | -9.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
AVTR
Avantor
15.34
1.05
7.35%
AZTA
Azenta
38.75
6.30
19.41%
RGEN
Repligen
181.70
32.97
22.17%
WST
West Pharmaceutical Services
364.98
93.27
34.33%
BLFS
BioLife Solutions
37.30
10.71
40.28%
STVN
Stevanato Group
20.20
-5.69
-21.97%
Avantor Corporate Events
Business Operations and StrategyExecutive/Board Changes
Avantor Names Todd Garner as New Chief Financial Officer
Positive
Sep 21, 2026
On September 21, 2026, Avantor, Inc. appointed Todd Garner as Executive Vice President and Chief Financial Officer, with Garner joining the Executive Leadership Team as the company’s principal financial officer. The move ends the interim CFO...
Business Operations and StrategyExecutive/Board Changes
Avantor Appoints Todd Garner as New Chief Financial Officer
Positive
Sep 21, 2026
On September 21, 2026, Avantor announced that Todd Garner was appointed Executive Vice President and Chief Financial Officer, joining the executive leadership team and serving as the company’s principal financial officer. He will oversee glo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.